Table 1 Clinical trials on targeting neutrophil relevant strategies in cancers
Purpose | Targets | Agents | Clinical Trials |
|---|---|---|---|
Inhibition of recruitment and promotion of apoptosis | CXCR1/ CXCR2 inhibitor | Reparixin | NCT02370238 |
NCT02001974 | |||
TRAIL receptor agonists | Tigatuzumab | NCT01307891 | |
CS-1008 | NCT01220999 | ||
Mapatumumab | NCT01088347 | ||
AMG 951 | NCT00508625 | ||
TRM-1 | NCT00092924 | ||
Anti- CD40 monoclonal antibody | CP-870, 893 | NCT01103635 | |
NCT00607048 | |||
CCR5 antagonists | Maraviroc | NCT03274804 | |
NCT01736813 | |||
CD47–SIRPα inhibitors | Hu5F9-G4 | NCT02216409 | |
IBI188 | NCT03717103 | ||
CC-90,002 | NCT02367196 | ||
Inhibition of pro-tumor function | Neutrophil elastase inhibitors | Sivelestat | NCT01170845 |
PI3K inhibitors | Buparlisib (a PI3Kδγ inhibitor) | NCT02194049 | |
NCT01629615 | |||
PDE5 inhibitors | Sildenafil | NCT02544880 | |
NCT00752115 | |||
Tadalafil | NCT01697800 | ||
NSAIDs | Aspirin and ibuprofen (COX1 and COX2 inhibitors) | NCT01786200 | |
Celecoxib (a COX2 inhibitor) | NCT02429427 | ||
Enhancing the tumor-promoting function(Switch phenotype) | C/EBPα | MTL-CEBPA small activating RNA | NCT02716012 |
NCT04105335 | |||
TGF-β pathway inhibitors | Galunisertib | NCT01582269 | |
NCT01682187 | |||
NCT03206177 | |||
NCT02672475 | |||
NCT02734160 | |||
NCT02452008 | |||
Fresolimumab (an anti- TGFβ monoclonal antibody) | NCT02581787 | ||
STAT3 inhibitors | Napabucasin (BBI608) | NCT02753127 | |
NCT02358395 | |||
β- Glucans | ImuCell WGP | NCT00682032 | |
Increasing recruitment and longevity | G- CSF mimetics | Pegfilgrastim | NCT00035594 |
YPEG- rhG-CSF (a long- acting form of pegfilgrastim) | NCT02005458 | ||
Angiogenesis inhibitors | Plinabulin (an inhibitor of tubulin polymerization, as required for the formation of new blood vessels) | NCT00630110 | |
NCT02504489 | |||
NCT03102606 |